Cystic Fibrosis Market 2015-2022 - Global Strategic Business Report 2017 - FDA Approves Vertex's ORKAMBI - Research and Markets
Here's a closer look at FDA commissioner nominee Scott Gottlieb's significant corporate ties
UPDATE: Here's a closer look at FDA commissioner nominee Scott Gottlieb's significant corporate ties
Concert Pharmaceuticals Reports Year Ended 2016 Financial Results
Health Care Down As Traders Hedge On Policy Outlook - Health Care Roundup
Carl Icahn Takes Stake in Bristol-Myers Squibb -- 2nd Update
New Pressure on Drug Giant -- WSJ
Domestic stocks have proved resilient in a tumultuous 2016.
Following is a roundup of stocks that recently jumped to 5 stars in the last week. By way of background, we award a stock 5 stars when it trades at a suitably large discount--i.e., a margin of safety--to our fair value estimate. Thus, when a stock hits 5-star territory, we consider it an especially ...
Recent clinical success in cystic fibrosis positions Vertex as a dominant player in this attractive rare-disease market.